276 related articles for article (PubMed ID: 24549401)
21. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
Akiyama H; Takase H; Kubo F; Miki T; Yamamoto M; Tomita M; Mochizuki M; Miura O; Arai A
Cancer Sci; 2016 Oct; 107(10):1458-1464. PubMed ID: 27412324
[TBL] [Abstract][Full Text] [Related]
22. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence.
Park YG; Park WK; Kim RY; Kim M; Park YH
Sci Rep; 2020 Oct; 10(1):15992. PubMed ID: 33009434
[TBL] [Abstract][Full Text] [Related]
23. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
24. Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.
Kitao M; Hashida N; Nishida K
BMC Ophthalmol; 2016 Jul; 16():103. PubMed ID: 27391815
[TBL] [Abstract][Full Text] [Related]
25. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
Kaburaki T; Taoka K
Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
[TBL] [Abstract][Full Text] [Related]
28. How we diagnose and treat vitreoretinal lymphoma.
Fend F; Ferreri AJ; Coupland SE
Br J Haematol; 2016 Jun; 173(5):680-92. PubMed ID: 27133587
[TBL] [Abstract][Full Text] [Related]
29. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
30. Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Porcu P; Martinez NL; Glass J; Mashayekhi A; Shields CL
Asia Pac J Ophthalmol (Phila); 2020; 9(2):110-116. PubMed ID: 31923035
[TBL] [Abstract][Full Text] [Related]
31. Two types of initial ocular manifestations in intraocular-central nervous system lymphoma.
Matsuo T; Yamaoka A; Shiraga F; Matsuo N
Retina; 1998; 18(4):301-7. PubMed ID: 9730171
[TBL] [Abstract][Full Text] [Related]
32. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
Kvopka M; Lake SR; Smith JR
Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
[TBL] [Abstract][Full Text] [Related]
33. Primary intraocular lymphoma: A review.
Choi JY; Kafkala C; Foster CS
Semin Ophthalmol; 2006; 21(3):125-33. PubMed ID: 16912010
[TBL] [Abstract][Full Text] [Related]
34. Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.
Iizuka-Honma H; Takizawa H; Mitsumori T; Okura H; Ishii H; Noguchi M
Intern Med; 2023 Feb; 62(3):459-463. PubMed ID: 35793963
[TBL] [Abstract][Full Text] [Related]
35. Curious case of bilateral non-resolving vitritis - Unmasking the masquerade on ultra-widefield imaging.
Delhiwala K
Indian J Ophthalmol; 2022 Apr; 70(4):1438-1439. PubMed ID: 35326082
[TBL] [Abstract][Full Text] [Related]
36. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
37. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
38. Ocular and central nervous system lymphoma: clinical features and diagnosis.
Cassoux N; Merle-Beral H; Leblond V; Bodaghi B; Miléa D; Gerber S; Fardeau C; Reux I; Xuan KH; Chan CC; LeHoang P
Ocul Immunol Inflamm; 2000 Dec; 8(4):243-50. PubMed ID: 11262654
[TBL] [Abstract][Full Text] [Related]
39. Two cases of primary vitreoretinal lymphoma: a diagnostic challenge : The supporting role of multimodal imaging in the diagnosis of primary vitreoretinal lymphoma.
Morara M; Foschi F; Veronese C; Torrazza C; Bacci F; Stefoni V; Ciardella PA
Int Ophthalmol; 2018 Feb; 38(1):353-361. PubMed ID: 28039672
[TBL] [Abstract][Full Text] [Related]
40. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
